Simultaneous overexpression of c-MET and EGFR in TNBC is associated with worse clinicopathological features and unfavorable outcomes. Although the development of new c-MET inhibitors and the emergence of 3rd-generation EGFR inhibitors represent promising treatment options, the high costs involved limit ...
Liu, Minetta CStorniolo, Anna MariaCarpenter, John TPuhalla, ShannonNanda, RitaMelhembertrandt, AmalLin, Nancy UJournal of Clinical OncologyAnders CK, Deal AM, Abramson GV, Liu MC, Storniolo AM, Carpenter JT, et al. TBCRC 018: phase II study of iniparib plus ...